New Combo Lung Cancer Therapy Improves Survival Over Single-Line Treatment
نویسندگان
چکیده
منابع مشابه
Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer.
BACKGROUND There are data showing that human leukemia cell lines have mRNA for an immunomodulatory protein found in normal pregnancy that is stimulated by progesterone. One of the functions of this progesterone-induced blocking factor (PIBF) is to suppress natural killer cell activity. Mifepristone has not only been shown to down-regulate PIBF expression by human leukemic cell lines but has als...
متن کاملLocal Therapy Improves Survival in Metastatic Prostate Cancer.
BACKGROUND Treatment of the primary, termed local therapy (LT), may improve survival in metastatic prostate cancer (mPCa) versus no local therapy (NLT). OBJECTIVE To assess cancer-specific mortality (CSM) after LT versus NLT in mPCa. DESIGN, SETTING, AND PARTICIPANTS Within the Surveillance, Epidemiology and End Results database (2004-2013), 13 692 mPCa patients were treated with LT (radica...
متن کاملI-124 pre-therapy dosimetry for the treatment of differentiated thyroid cancer: A single center experience
Introduction:The maximum tolerable activity (MTA) of I-131 in radioiodine therapy is an established surrogate quantity to ensure that the therapeutic activity does not produce severe damages to the bone marrow and lung. The aim of this study was to estimate the MTAs for high-risk patients using I-124 pre-therapy dosimetry and to compare the results with published literature. <...
متن کاملFirst-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
BACKGROUND Lung cancer is a malignant carcinoma which has the highest morbidity and mortality in Chinese population. Gefitinib, a tyrosine kinase (TK) inhibitor of epidermal growth factor receptor (EGFR), displays anti-tumor activity. The present data regarding first-line treatment with single agent gefitinib against non-small-cell lung cancer (NSCLC) in Chinese population are not sufficient. ...
متن کاملThird-line therapy in advanced non-small cell lung cancer.
PURPOSE With the improvements in first- and second-line treatments in non-small cell lung cancer (NSCLC), there is an increasing number of patients who receive third-line therapy. No other standard choice for third-line therapy aside from erlotinib is possible. This study investigated the efficacy and safety of single-agent chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibito...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Medical Sciences
سال: 2011
ISSN: 1682-4474
DOI: 10.3923/jms.2011.314.314